Literature DB >> 9631876

Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy.

A P Vakeva1, A Agah, S A Rollins, L A Matis, L Li, G L Stahl.   

Abstract

BACKGROUND: Myocardial ischemia and reperfusion (MI/R)-induced tissue injury involves necrosis and apoptosis. However, the precise contribution of apoptosis to cell death, as well as the mechanism of apoptosis induction, has not been delineated. In this study, we sought to define the contribution of the activated terminal complement components to apoptosis and necrosis in a rat model of MI/R injury. METHODS AND
RESULTS: Monoclonal antibodies (mAbs; 18A and 16C) raised against the rat C5 complement component bound to purified rat C5 (ELISA). 18A effectively blocked C5b-9-mediated cell lysis and C5a-induced chemotaxis of rat polymorphonuclear leukocytes (PMNs), whereas 16C had no complement inhibitor activity. A single dose (20 mg/kg i.v.) of 18A blocked >80% of serum hemolytic activity for >4 hours. Administration of 18A before myocardial ischemia (30 minutes) and reperfusion (4 hours) significantly reduced (91%) left ventricular free wall PMN infiltration compared with 16C treatment. Treatment with 18A 1 hour before ischemia or 5 minutes before reperfusion significantly reduced infarct size compared with 16C treatment. A significant reduction in infarct size (42%) was also observed in 18A-treated rats after 30 minutes of ischemia and 7 days of reperfusion. DNA ladders and DNA labeling (eg, TUNEL assay) demonstrated a dramatic reduction in MI/R-induced apoptosis in 18A-treated compared with 16C-treated rats.
CONCLUSIONS: Anti-C5 therapy in the setting of MI/R significantly inhibits cell apoptosis, necrosis, and PMN infiltration in the rat despite C3 deposition. We conclude that the terminal complement components C5a and C5b-9 are key mediators of tissue injury in MI/R.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631876     DOI: 10.1161/01.cir.97.22.2259

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  92 in total

1.  Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation.

Authors:  C Mold; C A Morris
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

2.  An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury.

Authors:  E Noiri; T Yokomizo; A Nakao; T Izumi; T Fujita; S Kimura; T Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  Ischemia/reperfusion injury of primary porcine cardiomyocytes in a low-shear microfluidic culture and analysis device.

Authors:  Grishma Khanal; Kiyong Chung; Ximena Solis-Wever; Bradley Johnson; Dimitri Pappas
Journal:  Analyst       Date:  2011-01-27       Impact factor: 4.616

Review 4.  Complement in ischemia reperfusion injury.

Authors:  Niels C Riedemann; Peter A Ward
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 5.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

6.  A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues.

Authors:  Ledia Goga; Sathnur B Pushpakumar; Gustavo Perez-Abadia; Paul Olson; Gary Anderson; Chirag V Soni; John H Barker; Claudio Maldonado
Journal:  J Surg Res       Date:  2010-10-16       Impact factor: 2.192

7.  Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis.

Authors:  Vasile I Pavlov; Mikkel-Ole Skjoedt; Ying Siow Tan; Anne Rosbjerg; Peter Garred; Gregory L Stahl
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

Review 8.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

Review 9.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model.

Authors:  Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.